Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
Trial ID: NCT04879563
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Phase: PHASE2
Start date: 2021-02-01
Completion date: 2025-08-30
Sponsor: Region Örebro County
Collaborators: UBITECH; ATOS; Siemens Corporation, Corporate Technology; Intrasoft; University of Patras; FORTH - Foundation for Research and Technology Hellas; Sphynx Technology Solutions AG; Faculty of Sciences, University of Novi Sad, Serbia; DFKI - German Research Center for Artificial Intelligence; CareAcross; National and Kapodistrian University of Athens; Fundacio Clinic Barcelona; Arthur's Legal; Fundacion iSYS
Conditions: Breast Cancer; Prostate Cancer; Quality of Life; Survivorship; Toxicity
Interventions: ASCAPE-based follow-up strategy
Locations: Urology Department, Sismanogleio General Hospital; Oncology Department, Hospital Clínic de Barcelona; Department of Oncology, Örebro University Hospital; Department of Oncology, University Hospital of Uppsala; CareAcross
Countries: Greece; Spain; Sweden; Sweden; United Kingdom
Enrollment: 500
Age range: 18 Years - None
Sex: ALL

Summary:
ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.

Eligibility criteria:
The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH).

One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital.

Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services.

Inclusion Criteria (breast cancer; ORB and Uppsala):

* breast cancer diagnosis
* no clinical evidence of metastatic disease
* able for curative treatment with surgery with or without oncological treatment.

Inclusion Criteria (breast cancer; Barcelona)

* prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last).

Inclusion Criteria (breast cancer; CareAcross)

* breast cancer diagnosis (as per self-reported) irrespective of stage and treatment.

Inclusion Criteria (prostate cancer; SGHA and ORB)

* proostate cancer diagnosis
* no clinical evidence of metastatic disease
* able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination).

Inclusion Criteria (prostate cancer; CareAcross)

* prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment.

Exclusion Criteria (common in all study sites):

* inability to give informed consent
* inability / no access to smartphones, applications or internet services
* patients with known medical history of allergy to the wearable material.

Outcomes:
Patients' experience using ASCAPE-based follow-up